Hyloris Pharmaceuticals SA Stock price

Equities

HYL

BE0974363955

Pharmaceuticals

Real-time Euronext Bruxelles 07:36:06 2024-03-28 am EDT 5-day change 1st Jan Change
11.4 EUR +3.17% Intraday chart for Hyloris Pharmaceuticals SA +2.70% -10.59%
Sales 2024 * 12.2M 13.15M Sales 2025 * 25.5M 27.49M Capitalization 309M 334M
Net income 2024 * -12M -12.94M Net income 2025 * -4M -4.31M EV / Sales 2024 * 24 x
Net cash position 2024 * 16.45M 17.74M Net cash position 2025 * 16.2M 17.47M EV / Sales 2025 * 11.5 x
P/E ratio 2024 *
-21 x
P/E ratio 2025 *
-55.3 x
Employees 42
Yield 2024 *
-
Yield 2025 *
-
Free-Float 43.38%
More Fundamentals * Assessed data
Dynamic Chart
Hyloris Pharmaceuticals SA Provides Earnings Guidance for 2024 CI
Transcript : Hyloris Pharmaceuticals SA, 2023 Earnings Call, Mar 14, 2024
Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hyloris Partner Hikma Launches Pain Medication in US, Obtains Approval in Canada MT
Hyloris Starts Patient Recruitment in Late-stage Trial for Proprietary Oral Rinse MT
Hyloris Pharmaceuticals SA Enrolls First Patient in Phase 3 Clinical Trial for Its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures CI
AFT Pharmaceuticals' Licensee Launches Pain Relief Medication in US; Shares Rise 4% MT
AFT Pharmaceuticals’ Maxigesic IV Launches in the US MT
Hyloris Pharmaceuticals SA Announces Positive Results for the Phase 2 Trial of Miconazole Domiphen-Bromide (MCZ-DB) in Patients with Acute Vulvovaginal Candidiasis CI
AFT Pharmaceuticals Ties Up with Belgian Firm to Develop Skin Medication MT
Hyloris Pharmaceuticals SA Enters into Partnership with AFT Pharmaceuticals to Develop a Novel Mucoadhesive Film for the Treatment of Vulvar Lichen Sclerosus CI
Hyloris Pharmaceuticals Wins US FDA's Orphan Drug Designation for Leukemia Treatment MT
AFT Pharmaceuticals Ties Up with Hyloris to Develop Burning Mouth Syndrome Treatment Candidate MT
AFT Pharmaceuticals Limited Enters into Partnership with Hyloris Pharmaceuticals CI
Hyloris Pharmaceuticals Partner Gets US FDA Nod for Warts Gel MT
More news

Latest transcript on Hyloris Pharmaceuticals SA

1 day+3.17%
1 week+2.70%
Current month-6.94%
1 month-7.32%
3 months-10.94%
6 months-3.39%
Current year-10.59%
More quotes
1 week
11.00
Extreme 11
11.50
1 month
11.00
Extreme 11
13.30
Current year
11.00
Extreme 11
13.30
1 year
10.60
Extreme 10.6
14.10
3 years
10.60
Extreme 10.6
19.10
5 years
8.80
Extreme 8.8
19.10
10 years
8.80
Extreme 8.8
19.10
More quotes
Managers TitleAgeSince
Founder 50 11-12-31
Founder 48 11-12-31
Director of Finance/CFO 53 21-09-22
Members of the board TitleAgeSince
Director/Board Member 66 19-12-31
Director/Board Member 74 19-12-31
Director/Board Member 75 19-12-31
More insiders
Date Price Change Volume
24-03-28 11.4 +3.17% 10 574
24-03-27 11.05 -0.45% 40,107
24-03-26 11.1 -1.77% 3,914
24-03-25 11.3 +1.80% 8,841
24-03-22 11.1 0.00% 19,438

Real-time Euronext Bruxelles, March 28, 2024 at 05:52 am EDT

More quotes
Hyloris Pharmaceuticals SA is a specialty biopharma company identifying and unlocking hidden potential in existing medications for the benefit of patients and the healthcare system. Hyloris applies its knowhow and technological innovations to existing pharmaceuticals and has built a broad proprietary product pipeline that has the potential to offer significant advantages over currently available alternatives. Hyloris Pharmaceuticals SA currently has two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid analgesic for the treatment of pain. The Company's development strategy primarily focuses on the FDA's 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule has already been established.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.05 EUR
Average target price
20.65 EUR
Spread / Average Target
+86.88%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Hyloris Pharmaceuticals SA - Euronext Bruxelles